Kornimate/medical-research-clean huggingface dataset:
effectiveness of a natural ingredient on obesity

Conditions: Overweight and Obesity; High Blood Pressure

Summary: randomized, placebo-controlled clinical trial, with two parallel branches whose objective is to evaluate the efficacy of the product investigated on blood pressure and fat mass of subjects without pharmacotherapy.

the subjects that meet the selection criteria will make a total of five visits to the research laboratory and will carry out the pre-established tests in the protocol. subsequently, a statistical analysis will be carried out with the variables measured in the study to obtain results.

Eligibility criteria:
inclusion criteria: * subjects of both sexes with age between 18-65 years. * subjects with a body mass index greater than 25 and less than 35. * volunteers capable of understanding the clinical study and willing to comply with the procedures and requirements of the study. exclusion criteria: * subjects under treatment that may affect body weight. * subjects with acute diseases. * volunteers with a history or presence of chronic pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunological, dermatological, urological, neurological, psychiatric, cardiovascular or pathology or malignant tumor disease. * subjects undergoing major surgery in the last 3 months. * subjects who quit smoking in the last 6 months or who intend to quit during the study. * subjects with allergies or eating disorders. * volunteers who are participating in another study that includes blood draws or dietary intervention. * pregnant or breastfeeding woman. * subjects whose condition does not make them eligible for the study, according to the researcher.
does preconditioning affects other organs in patients undergoing open heart surgery ?

Conditions: Neutrophil Lymphocyte Ratio; Serum Createnine; Mechanical Ventilation

Summary: an association between white blood cell count (wbc), neutrophil-lymphocyte ratio , and inflammatory process is well known . ischemic preconditioning reduces the inflammation

preliminary evidence has suggested the role of inflammation in development and prognosis of cardiovascular diseases and cancers. most of the prognostic studies failed to account for the effects of co-morbid conditions as these might have raised the systemic inflammation. we used neutrophil lymphocyte ratio (nlr) as a measure of systemic inflammation and investigated its association with cardiac preconditioning in open heart surgery .

Eligibility criteria:
inclusion criteria: * 18-60 years old * american society of anesthesiologists physical status ii and iii * patients scheduled for open heart surgery * no active inflammatory process exclusion criteria:exclusion criteria: * emergency surgery * clinically significant kidney or liver disease * patients allergic to local anesthetic * patients with prolonged cardiopulmonary bypass time (\>120 min) * patients required intra-aortic balloon pump * postoperative hemodynamic instability (including the occurrence of serious arrhythmia) or bleeding that required surgical re-exploration

Keywords: cardiac preconditioning open heart surgery createnine inflammation
efficacy of albuterol in the treatment of congenital myasthenic syndromes

Conditions: Congenital Myasthenic Syndrome

Summary: the study tests the notion that patients suffering from certain types of congenital myasthenic syndromes are benefitted by the use of albuterol at doses used in clinical practice.

the aim of the proposal is to evaluate the effects of albuterol, an adrenergic agonist, in the treatment of congenital myasthenic syndromes (cms). over the past 2 decades i found that some cms patients refractory to or worsened by cholinergic agonists, namely those suffering from defects in acetylcholinesterase (ache) or dok-7, respond to ephedrine, a medication used for over half-a-century in the treatment of autoimmune myasthenia gravis. after ephedrine became unavailable, i treated the same type of patients with albuterol in doses ranging from 4 mg daily to twice daily for adults; the dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily. evaluation of the effects of the medications are based on the table shown below. name: mayo clinic no: date of this report: (dd/mm/yyyy): before taking albuterol er on albuterol (date of this report) * current daily dose of albuterol: dates when started (d/m/year) daily dose distance in feet walked without stopping to rest number of steps climbed without stopping to rest difficult to sit up from lying on back\* difficult to rise from sitting\* difficult to speak or swallow\* shortness of breath on exertion\* shortness of breath at night\* weakness of arm or hand muscles \* weakness of leg or foot muscles\* \*rate as mild, moderate, severe describe below any additional changes in your condition such as arm elevation time, number of deep knee bends before having to stop, or in activities of daily living relevant to the effects of the treatment. also indicate any unwanted side effects of the medication. continue on other side or separate page if necessary. return this questionnaire to dr. andrew engel (email:schaefer.cleo@mayo.edu) ,after treatment with albuterol for 1 month and then monthly thereafter, or mail to dr. andrew engel, department of neurology, mayo clinic, rochester, mn 55905.

Eligibility criteria:
inclusion criteria: * diagnosis of congenital myasthenic syndrome substantiated by typical clinical history, seronegativity to achr and musk, and evidence of a decremental emg response. exclusion criteria: * uncontrolled hypertension, arrhythmias, or other significant cardiac disease.

Keywords: congenital myasthenic syndrome albuterol neuromuscular transmission
mobile health-based motivational interviewing to promote covid-19 vaccination

Conditions: Vaccination Hesitancy

Summary: the objective of this study is to evaluate the preliminary efficacy and acceptability of an mobile health-based motivational interviewing (mi) intervention to promote sars-cov-2 vaccination (motivacc) compared to traditional phone-based mi.


Eligibility criteria:
inclusion criteria: * \>18 years * reside in a rural area * no previous dose of a sars-cov-2 vaccine * speak english * able to provide informed consent exclusion criteria: * a cognitive or other disability that inhibits smart phone use * inability to participate because of medical or psychiatric conditions diagnosed by a physician/clinician * enrollment in other covid-19 research; pregnant or lactating
clinical trial to assess safety and immunogenicity of a synthetic vaccine against streptococcus pyogenes

Conditions: Rheumatic Fever

Summary: this is a double-blind, randomized, placebo-controlled phase i clinical trial with dose-escalation of a synthetic vaccine against streptococcus pyogenes. the active component of this vaccine candidate is a synthetic polypeptide named streptincor designed to elicit humoral and cell-mediated immune responses. the vaccine will be formulated with aluminium hydroxide in three different doses of streptincor (50 µg, 100µg, 200 µg). the proposed vaccination schedule is three doses (0, 1, 6 months). the doses will be escalated for the next group after safety review.


Eligibility criteria:
inclusion criteria: * healthy volunteers, both sex, aging 18 to 45 years; * availability for all procedures during the study period; * provide free informed consent to join the study exclusion criteria: * diagnosis of concomitant infections or diseases that might affect immunity, including active hiv infection, hepatitis b, hepatitis c, diabetes mellitus, neoplasias, and autoimmune diseases; * previous or current diagnosis or family antecedent of rheumatic fever, chorea, obsessive-compulsive disorder or glomerulonephritis; * previous or current diagnosis of cardiac disease; * severe asma or chronic obstructive pulmonary disease (copd); * abnormal neurological clinical assessment, particularly chorea; * use of treatments that might affect the immunity in the last four weeks, including immunomodulators, corticosteroids (only systemic use equal or longer than two weeks), or antineoplastic agents; * use of treatments that might affect heart valves in the latest four weeks, including fenfluramine e dexfenfluramine; * kidney failure determined by creatinine clearance lower than 45 ml/min/1,73m²; * history of intolerance or allergy to any component of investigational products, including antigen or adjuvant; * presence of abnormalities in heart valves or heart anatomy defined by echocardiogram; * electrocardiogram disturbances; * presence of cross-reactive antibodies against human tissues (heart, kidney, cartilage, brain) in screening tests; * evidence or suspicion of recent infection due to s. pyogenes assessed by clinical symptoms and negative rapid test for streptococcus; * pregnancy, breastfeeding mother or intention to became pregnant during the study period; * any other condition that might affect the study process according to the investigators.

Keywords: vaccine peptide streptococcus pyogenes
enlicitide decanoate (mk-0616 oral pcsk9 inhibitor) renal impairment study (mk-0616-020)

Conditions: Hypercholesterolaemia

Summary: the primary objective of the study is to compare the plasma pharmacokinetics (pk) of enlicitide decanoate following a single 20 mg dose in participants on a background of statin therapy with varying degrees of renal impairment (moderate, severe, end stage renal disease \[esrd\]) to those of healthy mean matched control participants on a background of statin therapy. there is no formal hypothesis.

panel c included participants with esrd. no urine samples could be obtained on panel c participants and hence no pharmacokinetic (pk) analysis could be performed for panel c participants as pre-specified in the protocol.

Eligibility criteria:
inclusion criteria: * be in good health with the exception of renal impairment (ri) and hypercholesterolemia for participants in panels a, b, and c. participants with ri that have stable, chronic medical or psychiatric conditions, including but not limited to hypertension, hypercholesterolemia, diabetes mellitus, hyper- or hypothyroidism, gout, and chronic anxiety or depression may be included at the discretion of the investigator * body mass index (bmi) ≥ 18 kg/m\^2 and ≤ 40 kg/m\^2, inclusive * be on a stable dose of any statin therapy defined as: no changes to dose or type of statin therapy for at least 2 months prior to screening and participant anticipates no changes to statin therapy throughout the study until the poststudy visit exclusion criteria: * history or presence of renal artery stenosis * had a functioning renal transplant in the past 5 years and is taking transplant medication * participants in panels a, b and d: has rapidly fluctuating renal function as determined by historical measurements * has a history gastrointestinal disease which might affect food and drug absorption, as determined by the investigator, or has had gastric bypass or similar surgery * history of cancer (malignancy) * history of significant multiple and/or severe allergies, or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs or food * has received an anti-proprotein convertase subtilisin/kexin type 9 (pcsk9) small molecule treatment, monoclonal antibody, or short interfering rna (sirna) or rna interference (ie, inclisiran) within 12 months prior to screening * participants with ri (panels a, b, and c): taking medications to treat chronic medical conditions and/or conditions associated with renal disease, if participant has not been on a stable regimen for at least 1 month (other than statins, which require a stable dose for at least 2 months) prior to administration of the initial dose of study intervention, and/or is unable to withhold the use of the medication(s) within 4 hours prior to and 4 hours after administration of study intervention * participated in another investigational study within 4 weeks prior to the prestudy (screening) visit * consumes greater than 3 servings of alcoholic beverages per day * consumes excessive amounts, defined as greater than 6 servings of caffeinated beverages per day
using prep, doing it for ourselves

Conditions: HIV Prevention; PrEP

Summary: the aim of this study is to test the effectiveness of the using prep, doing it for ourselves (updos) intervention is to improve pre-exposure prophylaxis (prep) uptake for black women using the motivational prep cascade framework within a community engaged cluster-randomized controlled trial of intervention and control salon clusters. it is expected that compared to control, women in the updos intervention will have higher prep uptake. additionally, this study aims to examine the barriers and facilitators underlining prep decision-making among a subsample of black women in both intervention and control groups using quantitative surveys and qualitative individual interviews. lastly, the study aims to understand the facilitators influencing implementation of updos for future scalability using quantitative surveys and qualitative interviews grounded in the cfir (consolidated framework for implementation research) framework.


Eligibility criteria:
inclusion criteria: * black * cisgender female * ages 18+ exclusion criteria: * under 18 years of age * does not identify as black * not a cisgender female

Keywords: black women community-based research
incidence of uterine cesarean scar niche after cesarean delivery

Conditions: Cesarean Section; Dehiscence

Summary: to assess the incidence of cesarean scar niche and its risk factors in a prospectively collected population.

it will be carried out in gynecology and obstetrics department in beni-suef university hospital using ultrasound: six months after the cesarean delivery, participants will be invited to the gynecologic outpatient clinic or department for ultrasound (us) examination to detect the presence of the niche. women without contraception will be examined during the follicular phase of the menstrual cycle to avoid an eventual early pregnancy. otherwise, a random phase of the menstrual cycle will be accepted. women who are pregnant at the time of us will be excluded. women will be examined in the lithotomy position with an empty bladder. the uterus will be examined in a standardized way, with trans-vaginal us performed first. for the diagnosis of cesarean scar niche (defined as an anechoic defect in the anterior wall of the lower uterine segment, communicating with the endometrial cavity),we will use a predetermined definition of a defect at least 2.0 mm deep

Eligibility criteria:
inclusion criteria: 1. delivery by cesarean section. 2. more than 6 months after delivery. 3. cesarean section by senior resident or assistant lecturer. exclusion criteria: 1. single layer technique in uterine closure. 2. uterine anomaly.
haploidentical bone marrow transplant with post-transplant cyclophosphamide for patients with severe aplastic anemia

Conditions: Severe Aplastic Anemia

Summary: severe aplastic anemia is a rare and serious form of bone marrow failure related to an immune-mediated mechanism that results in severe pancytopenia and high risk for infections and bleeding. patients with matched sibling donors for transplantation have a 80-90% chance of survival; however, a response rate with just immunosuppression for those patients lacking suitable hla-matched related siblings is only 60%. with immunosuppression, only 1/3 of patients are cured, 1/3 are dependent on long term immunosuppression, and the other 1/3 relapse or develop a clonal disorder. recent studies have shown that using a haploidentical donor for transplantation has good response rates and significantly lower rates of acute and chronic gvhd.

mismatched haploidentical donors will be identified for patients with severe aplastic anemia. these patients will undergo a preparative regimen of fludarabine/cyclophosphamide/tbi followed by haploidentical bone marrow transplantation. post-transplant cyclophosphamide will be administered on days 3 \& 4. immunosuppression with tacrolimus and mmf will begin on day +5; mmf will be discontinued on day +35 while tacrolimus continues until day +180. investigators hypothesize that haploidentical transplantation with the above-mentioned preparative regimen will have a \<30% graft failure rate. the one-sided exact binomial test at 5% significance level will be used to test this hypothesis. the size of 20 patients provides the power of 92.5% for confirming the 30-day graft failure rate \<30%.

Eligibility criteria:
inclusion criteria: * availability of 3/6 - 5/6 matched (hla-a, b, dr) related donor who must have negative hla cross-match in the host vs. graft direction * age \<= 65 years for previously treated and \<= 75 years for previously treated patients * kps \>= 70% * aplastic anemia that meets the following criteria: peripheral blood (must fulfill 2 of 3): * \<500 pmn/mm3 * \<20,000 platelets * absolute reticulocyte count \<40,000/microl bone marrow (must be either): * markedly hypocellular (\<25% of normal cellularity) * moderately hypocellular with 70% non-myeloid precursors and patient meets peripheral blood criteria above exclusion criteria: * poor cardiac function (lvef \<40%) * poor pulmonary function (fev1 \& fvc \<50% predicted) * poor liver function (bili \>= 2mg/dl) * poor renal function (creatinine \>= 2.0mg/dl or creatinine clearance \<40ml/min) * prior allogeneic transplant

Keywords: saa
effects of standing on glycemia in prediabetic adults

Conditions: Prediabetes

Summary: the study is a crossover, pilot trial examining the acute effects of standing on blood sugar in prediabetic, working adults. participants will complete oral glucose tolerance testing, once while sitting and once while standing. they will also wear a continuous blood sugar monitor once while sitting at their desk for a week and once while using their desk as a sit-stand desk with a goal of standing intermittently for at least half of the work day. physical activity levels will be measured with an accelerometer. the primary study hypothesis is that blood sugar will differ between the sitting and standing conditions for each of the tests performed.


Eligibility criteria:
inclusion criteria: * fasting blood glucose \>100 mg/dl * employed full-time working at least 35 hours/week * able to safely begin a light physical activity program exclusion criteria: * heart disease * renal disease * peripheral neuropathy * retinopathy * pad * lower limb amputation * pregnancy * active substance abuse * current smoker * psychiatric disorder * severe visual impairment * immune-compromised individuals, * enrollment in a physical activity study * use of insulin or an insulin pump

Keywords: prediabetes physical inactivity sedentary standing
combination of serratus anterior and pectoral nerve blocks (pecs ii) as main anesthetic method in breast cancer surgery

Conditions: Anesthesia

Summary: aim of this study is to determine the success of combined serratus anterior and pecs-2 block as the main anesthetic method in breast cancer surgery and also to investigate the patient acceptability of this combination and its relationship with surgeon satisfaction.

breast conserving surgery or mastectomy is applied in the surgical treatment of breast cancer. axillary interventions range from sentinal lymph node biopsy to lymph node dissection. clinically significant acute pain develops following breast surgery in 35% of patients. today, regional anesthesia is widely used as an opioid-sparing strategy in the treatment of acute postoperative pain. new fascial plane blocks have been developed as alternative or complementary techniques for chest wall analgesia, including pectoral nerve blocks (pecs1-2) and serratus plane block. in order to reduce the risk of perioperative morbidity and mortality and to meet the patient demand, the demand for awake surgery is increasing in institutions. therefore, a prospective observational case series was conducted to explain the efficacy, patient acceptability, and surgeon satisfaction of combined serratus anterior and pecs-2 block as the main anesthetic method for breast cancer surgery.

Eligibility criteria:
inclusion criteria: * patients between the ages of 18-80 and asa i-iii who will undergo unilateral breast cancer surgery will be included in the study. exclusion criteria: * patients with previous breast surgery other than excisional biopsy, * coagulopathy, * bleeding disease, * local infection at the injection site, * history of local anesthetic allergy, * psychiatric disease (depression, mania, schizophrenia or antipsychotic drug use), * history of opioid use for more than 4 weeks * patients with body mass index (bmi) \>40kg/m2 and * chest deformity (pectus excavatum and pectus carinatum) will be excluded from the study.

Keywords: regional anesthesia interfascial plane block main anesthetic method
vaporization as a smokeless cannabis delivery system

Conditions: Healthy Volunteers

Summary: a study to evaluate the use of a vaporization system as a smokeless delivery system for inhaled marijuana.

our primary objective is to evaluate the use of a vaporization system ( the volcano) as a smokeless delivery system for inhaled marijuana. we will compare plasma levels of delta-9-tetrahydrocannabinol (thc), cannabinol, cannabidiol, and metabolites, including 11-oh-thc, in healthy volunteers after smoking \~400 mg each of approximately 1.8, 3.5, and 7% thc marijuana cigarettes (using the foltin puff procedure) to those obtained when the same individuals inhale the vaporization product of the rest of the marijuana from the identical cigarette processed through the volcano device. in addition to plasma levels, we will also compare the thc concentrations over an 8-hour time period, the subjective high experienced by the patients, and clinical evidence of cannabis effect by evaluating conjunctival hyperemia and heart rate. we will also compare the tolerability of the two methods of ingestion, and we will monitor expired carbon monoxide to evaluate whether the vaporizer reduces exposure to respiratory toxins.

Eligibility criteria:
inclusion criteria: * age 21-45 years current history use of marijuana. subjects must have smoked marijuana within the past 30 days but an amount totaling less than 10 marijuana cigarettes or the equivalent. all men and women in this study must agree to use adequate birth control during the study. acceptable barrier birth control methods are a male condom, female condom, diaphragm, or intra-uterine (iud). all women of reproductive potential (who have not reached menopause or undergone hysterectomy, oophorectomy,or tubal ligation) must have a negative urine b-hcg pregnancy test performed 48 hours before initiating the protocol-specified medication. able to understand and follow the instructions of the investigator and research personnel. able and willing to provide informed consent. exclusion criteria: * severe coronary artery disease, uncontrolled hypertension, cardiac ventricular conduction abnormalities, or orthostatic mean blood pressure drop greater than 24mm/hg, severe chronic obstructive pulmonary disease. history of renal or hepatic failure. evidence of hepatic, hematological or renal dysfunction based on judgement of physician. active substance abuse. marijuana dependence as defined in dsm-iv code#304.30. any psychiatric dysfunction that would, in the opinion of the study investigator, interfere with a participant's ability to comply with the study protocol. use of tobacco within the past 30 days. subjects taking medications which may be vulnerable to drug-drug interactions such as those metabolized by the cytochrome p450 enzyme system. blood donation in the past 30 days. use of smoked marijuana within 48 hours of gcrc admission. women who are pregnant or breast-feeding may not take part in this study. unable to read or speak english.

Keywords: cannabis marijuana vaporization volcano thc